Literature DB >> 35299263

Metabolic Consequences of Antiretroviral Therapy.

Caroline E Diggins1, Samuel C Russo1, Janet Lo2.   

Abstract

PURPOSE OF REVIEW: This review reports on published studies describing metabolic changes associated with antiretroviral therapy (ART) to treat HIV disease including a historical perspective of earlier ART agents, but with the main focus on newer ART agents currently in use. RECENT
FINDINGS: Studies from different countries around the world have shown that integrase inhibitor (INSTI)-based regimens as well as tenofovir alafenamide (TAF) are associated with weight gain, with women and people of black race at especially high risk. Some studies preliminarily suggest worsened metabolic outcomes associated with this weight gain including adverse effects on glucose homeostasis. Antiretroviral therapy can affect weight, adipose tissue, glucose, and lipids. As obesity is prevalent and increasing among people with HIV, awareness of risk factors for weight gain, including the ART medications associated with greater weight gain, are needed in order to inform prevention efforts. Further research is needed to better understand the long-term health consequences of INSTI- and TAF-associated weight increases.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Antiretroviral therapy; Cholesterol; Diabetes; Dyslipidemia; Integrase inhibitors; Weight gain

Mesh:

Substances:

Year:  2022        PMID: 35299263     DOI: 10.1007/s11904-022-00600-6

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  95 in total

1.  Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.

Authors:  D Périard; A Telenti; P Sudre; J J Cheseaux; P Halfon; M J Reymond; S M Marcovina; M P Glauser; P Nicod; R Darioli; V Mooser
Journal:  Circulation       Date:  1999-08-17       Impact factor: 29.690

2.  Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial.

Authors:  Véronique Joly; Philippe Flandre; Vincent Meiffredy; Nicolas Leturque; Marine Harel; Jean-Pierre Aboulker; Patrick Yeni
Journal:  AIDS       Date:  2002-12-06       Impact factor: 4.177

3.  Stavudine versus zidovudine and the development of lipodystrophy.

Authors:  J R Bogner; V Vielhauer; R A Beckmann; G Michl; L Wille; B Salzberger; F D Goebel
Journal:  J Acquir Immune Defic Syndr       Date:  2001-07-01       Impact factor: 3.731

4.  Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care.

Authors:  Heidi M Crane; Carl Grunfeld; James H Willig; Michael J Mugavero; Stephen Van Rompaey; Richard Moore; Benigno Rodriguez; Betsy J Feldman; Michael M Lederman; Michael S Saag; Mari M Kitahata
Journal:  AIDS       Date:  2011-01-14       Impact factor: 4.177

5.  The survival benefits of AIDS treatment in the United States.

Authors:  Rochelle P Walensky; A David Paltiel; Elena Losina; Lauren M Mercincavage; Bruce R Schackman; Paul E Sax; Milton C Weinstein; Kenneth A Freedberg
Journal:  J Infect Dis       Date:  2006-06-01       Impact factor: 5.226

6.  Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients.

Authors:  M A Valantin; R Bittar; P de Truchis; D Bollens; L Slama; P Giral; D Bonnefont-Rousselot; P Pétour; C Aubron-Olivier; D Costagliola; C Katlama
Journal:  J Antimicrob Chemother       Date:  2010-01-06       Impact factor: 5.790

7.  Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.

Authors:  Andrew Carr; Cassy Workman; Don E Smith; Jennifer Hoy; Jeff Hudson; Nicholas Doong; Allison Martin; Janaki Amin; Judith Freund; Matthew Law; David A Cooper
Journal:  JAMA       Date:  2002-07-10       Impact factor: 56.272

8.  A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.

Authors:  A Carr; K Samaras; S Burton; M Law; J Freund; D J Chisholm; D A Cooper
Journal:  AIDS       Date:  1998-05-07       Impact factor: 4.177

9.  Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy.

Authors:  S A Riddler; X Li; H Chu; L A Kingsley; A Dobs; R Evans; F Palella; B Visscher; J S Chmiel; Ar Sharrett
Journal:  HIV Med       Date:  2007-07       Impact factor: 3.180

10.  Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss.

Authors:  Marit G A van Vonderen; Michiel A van Agtmael; Elly A M Hassink; Ana Milinkovic; Kees Brinkman; Suzanne E Geerlings; Matti Ristola; Arne van Eeden; Sven A Danner; Peter Reiss
Journal:  PLoS One       Date:  2009-05-21       Impact factor: 3.240

View more
  1 in total

Review 1.  Weight Gain and Metabolic Syndrome in Human Immunodeficiency Virus Patients.

Authors:  Hyun-Ha Chang
Journal:  Infect Chemother       Date:  2022-05-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.